| 摘要 |
<p>Described herein are novel mutants of endostatin, one of which, designated 'EM 1', has anti-angiogenic activity similar or superior to that of wild type endostatin. The invention relates to the discovery of an isolated anti-angiogenic peptide, wherein the C-terminal end of the peptide comprises the amino acid sequence SYIVLCIE, which has anti-angiogenic properties. Designated 'EM 1', this protein comprises a mutated endostatin protein, where the mutation comprises a deletion of nine consecutive amino acids from the C-terminus of the mutated endostatin protein (e.g., NSFMTSFSK). EM 1 terminates in the amino acid sequence SYIVLCIE. The invention also comprises isolated polynucleotides encoding EM 1, operably linked to expression sequence, and host cells transformed with such a construct. Antibodies to EM 1 are also disclosed. The invention also relates to processes for producing EM 1, fusion proteins containing EM 1, and compositions comprising EM 1 or fusion products thereof. The invention also discloses methods of producing polypeptides encoding EM 1.</p> |
